Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

Abstract

European Union; German Centre for Infection Research; German Research Council; and German Ministry for Education and Research.

Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014

“…Virus shedding in urine has been observed in a human case up to 13 days after symptom onset, in stool up to 16 days and from oronasal swabs up to 16 days after onset of symptoms [31]. In another study, a tracheal aspirate sample was shown to be viral nucleotide positive 20 days after onset of disease [21].…”

What are our pharmacotherapeutic options for MERS-CoV?

“…In a systematic review of the use of convalescent plasma in SARSCoV, the effect of this modality was inconclusive as other factors may have played a role, such as patient comorbidities, extent of the disease or effect of other concomitant treatments [5]. The presence of MERS-CoV-specific antibodies was reported in two patients from Germany with a titer of 1:640 [6,7]. Whether convalescent plasma would be effective in the therapy of MERS-CoV is a question that remains to be answered.…”

Middle East respiratory syndrome coronavirus infection: a short note on cases with renal failure problem

“…In cases with viralinduced acute renal failure, the disappearance of virus in the urine sample is the important observation when renal failure occurs. 7 Accompanied with respiratory failure, acute renal failure can be the cause of death in the severely infected cases. 8 It is no doubt that the patients with underlying chronic renal problem especially those on hemodialysis have a high risk to get disease transmission from the other patients.…”